Occult hepatitis B in Iranian blood donors, an overview of the challenges: A narrative review.
blood donors
blood transfusion
hepatitis
infection
prevalence
Journal
Health science reports
ISSN: 2398-8835
Titre abrégé: Health Sci Rep
Pays: United States
ID NLM: 101728855
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
15
04
2023
revised:
07
07
2023
accepted:
18
07
2023
medline:
2
8
2023
pubmed:
2
8
2023
entrez:
2
8
2023
Statut:
epublish
Résumé
Occult hepatitis B infection (OBI) is a transfusion-transmitted infection. Although, screening the hepatitis B virus among blood donors can play an important role in increasing the health of blood products, OBI screening in blood transfusion centers is still a challenge. This review study aimed to appraise the challenges of OBI screening and its associated do's and don'ts in blood transfusion centers. In this review study, a search was conducted on the electronic databases of PubMed, Web of Science, Scopus, Ovid, Irandoc, and Magiran from January 1996 to December 2020. Also, cross-sectional studies that determined the prevalence of OBI or anti-HBc were included in the study. In addition, studies with incomplete data on the prevalence of OBI were excluded. The prevalence of OBI varies among Iranian blood donors. The rates reported by blood transfusion centers of Mashhad, Ahvaz, and Tehran were 0%, and Isfahan, Shiraz, and Kerman were 0.9%, 0.08%, and 2.36%, respectively. In areas with high prevalence of hepatitis B virus, OBI screening only by anti-HBc test led to the exemption of blood donors from donating blood. Avoiding OBI screening also effected the risk of virus transmission to blood recipients. Plasma products had a higher risk (85%) of virus transmission. Determining an appropriate screening strategy based on prevalence status, the cost-effectiveness of screening tests, and the policies of each blood transfusion center is essential.
Sections du résumé
Background
UNASSIGNED
Occult hepatitis B infection (OBI) is a transfusion-transmitted infection. Although, screening the hepatitis B virus among blood donors can play an important role in increasing the health of blood products, OBI screening in blood transfusion centers is still a challenge. This review study aimed to appraise the challenges of OBI screening and its associated do's and don'ts in blood transfusion centers.
Methods
UNASSIGNED
In this review study, a search was conducted on the electronic databases of PubMed, Web of Science, Scopus, Ovid, Irandoc, and Magiran from January 1996 to December 2020. Also, cross-sectional studies that determined the prevalence of OBI or anti-HBc were included in the study. In addition, studies with incomplete data on the prevalence of OBI were excluded.
Results
UNASSIGNED
The prevalence of OBI varies among Iranian blood donors. The rates reported by blood transfusion centers of Mashhad, Ahvaz, and Tehran were 0%, and Isfahan, Shiraz, and Kerman were 0.9%, 0.08%, and 2.36%, respectively. In areas with high prevalence of hepatitis B virus, OBI screening only by anti-HBc test led to the exemption of blood donors from donating blood. Avoiding OBI screening also effected the risk of virus transmission to blood recipients. Plasma products had a higher risk (85%) of virus transmission.
Conclusions
UNASSIGNED
Determining an appropriate screening strategy based on prevalence status, the cost-effectiveness of screening tests, and the policies of each blood transfusion center is essential.
Identifiants
pubmed: 37529253
doi: 10.1002/hsr2.1466
pii: HSR21466
pmc: PMC10388709
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e1466Informations de copyright
© 2023 The Authors. Health Science Reports published by Wiley Periodicals LLC.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Viruses. 2021 Oct 13;13(10):
pubmed: 34696483
J Infect Dev Ctries. 2010 Oct 28;4(10):658-61
pubmed: 21045360
Transfus Med. 2009 Aug;19(4):189-94
pubmed: 19708860
Transfus Apher Sci. 2011 Oct;45(2):195-7
pubmed: 21971311
Curr Opin Hematol. 2011 Nov;18(6):461-6
pubmed: 21912252
Transfusion. 2007 Jul;47(7):1197-205
pubmed: 17581154
J Infect Dev Ctries. 2012 Apr 13;6(4):340-6
pubmed: 22505444
Blood Transfus. 2017 Jan;15(1):6-12
pubmed: 27416568
Mediterr J Hematol Infect Dis. 2018 Jan 01;10(1):e2018007
pubmed: 29326804
Transfusion. 2010 Jul;50(7):1408-12
pubmed: 20636529
Transfusion. 2021 Aug;61(8):2402-2413
pubmed: 34114670
Virol J. 2016 Mar 05;13:36
pubmed: 26944046
Indian J Med Res. 2006 Jan;123(1):37-42
pubmed: 16567866
J Med Virol. 2018 Feb;90(2):263-270
pubmed: 28876463
Transfusion. 2020 Jul;60(7):1624-1632
pubmed: 32208532
Transfusion. 2013 Jul;53(7):1393-404
pubmed: 23033944
Int J Med Sci. 2020 Aug 25;17(15):2299-2305
pubmed: 32922195
Transfusion. 2013 Jul;53(7):1405-15
pubmed: 23362802
Lancet. 2005 Feb 19-25;365(9460):638-40
pubmed: 15721459
Semin Liver Dis. 2019 May;39(2):249-260
pubmed: 30912100
Transfus Med Hemother. 2017 Aug;44(4):263-272
pubmed: 28924431
Transfusion. 2019 Apr;59(4):1273-1282
pubmed: 30811608
Intern Med. 2017;56(15):1967-1971
pubmed: 28768965
Vox Sang. 2008 Feb;94(2):153-66
pubmed: 18205672
Vox Sang. 2004 Feb;86(2):83-91
pubmed: 15023176
Vox Sang. 2021 Feb;116(2):197-206
pubmed: 32996609
Transfusion. 2009 Oct;49(10):2214-20
pubmed: 19527477
Clin Lab. 2021 Jan 1;67(1):
pubmed: 33491423
World J Gastroenterol. 2016 Apr 7;22(13):3531-46
pubmed: 27053845
Blood Transfus. 2011 Oct;9(4):455-61
pubmed: 21839007
J Hepatol. 2020 Oct;73(4):952-964
pubmed: 32504662
World J Gastroenterol. 2011 Mar 28;17(12):1563-8
pubmed: 21472122
BMC Infect Dis. 2020 Oct 7;20(1):736
pubmed: 33028232
Vox Sang. 2019 May;114(4):e1-e35
pubmed: 30972757
World J Gastroenterol. 2018 Apr 14;24(14):1507-1520
pubmed: 29662289
Hepat Mon. 2013 Mar 17;13(3):e6590
pubmed: 23675384
J Med Virol. 2019 Apr;91(4):615-622
pubmed: 30345529
J Infect Dev Ctries. 2012 Aug 21;6(8):650-1
pubmed: 22910573
Asian J Transfus Sci. 2021 Jul-Dec;15(2):179-182
pubmed: 34908751
World J Hepatol. 2014 Jun 27;6(6):384-93
pubmed: 25018849
Arch Iran Med. 2020 Mar 01;23(3):189-196
pubmed: 32126788
Mol Diagn Ther. 2006;10(2):77-91
pubmed: 16669606
Jundishapur J Microbiol. 2016 Jul 03;9(7):e37329
pubmed: 27679708
Blood Transfus. 2015 Apr;13(2):227-32
pubmed: 25369612
Arch Iran Med. 2014 Feb;17(2):106-7
pubmed: 24527970
Nat Rev Gastroenterol Hepatol. 2020 Oct;17(10):618-634
pubmed: 32467580
Transfusion. 2008 May;48(5):1001-26
pubmed: 18454738
J Hepatol. 2019 Aug;71(2):397-408
pubmed: 31004683
PLoS One. 2015 Jul 06;10(7):e0131912
pubmed: 26148052
Hepat Mon. 2010 Winter;10(1):31-5
pubmed: 22308123